MEDI:GATE NEWS PanGen contracts with Huonslab for biopharmaceutical process characterization study

Posted on 04/04/2025 08:39Modified on 04/04/2025 08:39

[Press Release] On March 5, Huons Group PanGen (CEO Jaeseung Yoon) will conduct research services for Huonslab's biopharmaceutical product license. PanGen announced today that it has signed a research service contract with Huonslab for biopharmaceutical process characterization. The total value of the contract is KRW 800 million, and the process characterization research conducted through this contract is a service to design a standard process suitable for commercial-scale production of biopharmaceuticals, which is an essential item for applying for an item license. It must consider the quality characteristics of biopharmaceuticals and enable continuous production. PanGen's contract development and manufacturing (CDMO) services are based on its core technology, PanGen CHO-TECH, and biopharmaceutical productization technology. It is a one-stop service from the establishment of high-performance recombinant CHO production cell lines to the outsourced production of non-clinical and clinical samples using GMP production facilities. PanGen has successfully collaborated with Huonslab in the past, signing a contract for the production of biopharmaceutical clinical samples in 2023 and validation for product approval in 2024. PanGen became part of the Huons family of companies in December of last year. Based on its know-how in developing cell lines for biopharmaceutical production and establishing production processes, PanGen provides biopharmaceutical contract development and manufacturing (CDMO) services and manufactures and sells biosimilars. “Huons Group plans to strengthen its biopharmaceutical R&D and CDMO businesses in the future,” said a Huons representative. ”We will continue to lead the healthcare market by maximizing synergies among Huons Group family companies.”

제보 SHARE

PanGen contracts with Huonslab for biopharmaceutical process characterization study

[Press Release] On March 5, Huons Group PanGen (CEO Jaeseung Yoon) will conduct research services for Huonslab's biopharmaceutical product license.

PanGen announced today that it has signed a research service contract with Huonslab for biopharmaceutical process characterization.

The total value of the contract is KRW 800 million, and the process characterization research conducted through this contract is a service to design a standard process suitable for commercial-scale production of biopharmaceuticals, which is an essential item for applying for an item license. It must consider the quality characteristics of biopharmaceuticals and enable continuous production.

PanGen's contract development and manufacturing (CDMO) services are based on its core technology, PanGen CHO-TECH, and biopharmaceutical productization technology. It is a one-stop service from the establishment of high-performance recombinant CHO production cell lines to the outsourced production of non-clinical and clinical samples using GMP production facilities.

PanGen has successfully collaborated with Huonslab in the past, signing a contract for the production of biopharmaceutical clinical samples in 2023 and validation for product approval in 2024. PanGen became part of the Huons family of companies in December of last year.

Based on its know-how in developing cell lines for biopharmaceutical production and establishing production processes, PanGen provides biopharmaceutical contract development and manufacturing (CDMO) services and manufactures and sells biosimilars.

“Huons Group plans to strengthen its biopharmaceutical R&D and CDMO businesses in the future,” said a Huons representative. ”We will continue to lead the healthcare market by maximizing synergies among Huons Group family companies.”

SCRAP PRINT 제보 SHARE

메디게이트뉴스 (news@medigatenews.com)

이 기자의 다른 기사 보기

댓글보기(0)